EW
Edwards Lifesciences Corporation
Price as of Jul 17, 2026
EW earnings
Edwards Lifesciences Corporation earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $0.73 | $0.78 | +7.0% | $1.6B | +3.2% |
| Oct 30, 2025 | $0.60 | $0.67 | +12.4% | $1.6B | +3.7% |
| Jul 24, 2025 | $0.62 | $0.67 | +7.4% | $1.5B | +3.0% |
| Apr 23, 2025 | $0.60 | $0.64 | +7.4% | $1.4B | +0.9% |
| Oct 24, 2024 | $0.67 | $0.67 | +0.8% | $1.4B | -12.3% |
| Jul 24, 2024 | $0.69 | $0.70 | +1.4% | $1.4B | -16.2% |
| Apr 25, 2024 | $0.64 | $0.66 | +3.1% | $1.6B | +1.8% |
| Feb 6, 2024 | $0.64 | $0.64 | +0.0% | $1.5B | +2.7% |
| Oct 25, 2023 | $0.59 | $0.59 | +0.0% | $1.5B | +0.1% |
| Jul 26, 2023 | $0.65 | $0.66 | +1.5% | $1.5B | +1.8% |
| Jan 31, 2023 | $0.61 | $0.64 | +4.9% | $1.3B | +1.1% |
| Oct 27, 2022 | $0.62 | $0.61 | -1.6% | $1.3B | -1.1% |
Earnings call summary
Q1 FY2026 · April 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Building on strong 2025 performance, Q1 2026 achieved 12.7% self-growth. Focus on structural heart disease and innovation. Strategy underpinned by speed, agility, discipline. TAVR benefits from clinical focus on proactive disease management, long-term evidence of SAPIEN platform. TMTT's unique portfolio of therapies driving growth. Surgical expanding portfolio to address structural heart patients' needs. - Financial performance: Q1 sales growth strong, raised full-year sales guidance for total company and TAVR. Adjusted EPS guidance updated. Gross margin guidance maintained. R&D and SG&A expenses discussed.
Guidance
- Raised full-year 2026 total company sales guidance to 9%-11%, TAVR sales guidance to 7%-9%. - 2026 TMTT sales expected $740 - $780 million. Mid-single-digit sales growth expected in surgical. - Updated full-year earnings per share guidance to $2.95 - $3.05 per share. - Projected Q2 sales 1.66 - 1.74 billion dollars, adjusted earnings per share 70 cents - 76 cents.
Segment performance
TAVR: First quarter global sales of $1.2 billion, increased 11% year-over-year. U.S. sales healthy, international even faster. Full year TAVR self-growth guidance raised to 7-9%. TMTT: First quarter sales of $173 million, increase of approximately 42% year-over-year. Procedural growth in mitral and tricuspid in double digits. 2026 TMTT sales expected $740 - $780 million, 35-45% growth. Surgical: First quarter global sales of $276 million, increased 6% year-over-year. Continued adoption of Resilia therapies. Mid single digit sales growth expected in 2026.
Analyst Q&A
Q: David Roman with Goldman Sachs asked about TAVR industry data and drivers of guidance.
A: Discussed TAVR data like early TAVR for asymptomatic, 7-year and 10-year data, market growth and some share gain.
Q: Larry Beagleson with Wells Fargo asked about TAVR guidance and M3 impact.
A: TAVR guidance based on Q1 outperformance, market growth and some share. M3 launching in U.S. for tricuspid patients in Q4.
Q: Travis Seed with Bank of America asked about capacity and NCD.
A: Capacity managed well by health systems, NCD process ongoing.
Q: Robbie Marcus with JP Morgan asked about guidance rationale.
A: Guidance realistic based on Q1 performance, comps, and high bar from 2025 H2.
Q: Vijay Kumar with Evercore ISI asked about share count and weather impact.
A: Share count impacted by accelerated share repurchase, weather impact nominal.
Q: Joanne Wunsch with Citibank asked about R&D and CFO search.
A: R&D investment intentional, CFO search process ongoing.
Q: Matt Taylor with Jefferies asked about TAVR guidance and healthcare environment.
A: TAVR guidance based on Q1 outperformance and market growth, healthcare environment positive with RAPID policy.
Q: Matt Mixick with Barclays asked about Mitral rollout and TriGustin.
A: Sapien M3 rollout starting with clinical trial centers, details on Mitral and TriGustin engagement.
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-07-23.